Form 4: UNITED THERAPEUTICS CEO Sells Shares

Sentiment:

Insider Transaction (Form 4)


Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 27, 2026.

Summary

  • Option exercise/conversion: acquired 9,500 Common Stock at $135.42 ($1,286,490) on July 27, 2026; holds 333,943 after (Indirect).
  • Open-market sale: disposed of 680 Common Stock at $525.81 ($357,552) on July 27, 2026; holds 333,263 after (Indirect).
  • Open-market sale: disposed of 890 Common Stock at $527.14 ($469,152) on July 27, 2026; holds 332,373 after (Indirect).
  • Open-market sale: disposed of 650 Common Stock at $528.51 ($343,530) on July 27, 2026; holds 331,723 after (Indirect).
  • Open-market sale: disposed of 1,797 Common Stock at $529.75 ($951,959) on July 27, 2026; holds 329,926 after (Indirect).
  • Open-market sale: disposed of 1,121 Common Stock at $530.49 ($594,675) on July 27, 2026; holds 328,805 after (Indirect).
  • Open-market sale: disposed of 1,836 Common Stock at $531.65 ($976,107) on July 27, 2026; holds 326,969 after (Indirect).
  • Open-market sale: disposed of 1,529 Common Stock at $532.38 ($814,004) on July 27, 2026; holds 325,440 after (Indirect).
  • Open-market sale: disposed of 957 Common Stock at $533.53 ($510,590) on July 27, 2026; holds 324,483 after (Indirect).
  • Open-market sale: disposed of 40 Common Stock at $535.04 ($21,402) on July 27, 2026; holds 324,443 after (Indirect).
  • Option exercise/conversion: disposed of 9,500 Stock Option on July 27, 2026; holds 265,410 after (Indirect).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $5,038,971 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Martine A Rothblatt — Director, Officer (Chairperson & CEO)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-07-27Option exercise/conversionCommon Stock9,500$135$1.3M333,943
2026-07-27Open-market saleCommon Stock680$526$357.6K333,263
2026-07-27Open-market saleCommon Stock890$527$469.2K332,373
2026-07-27Open-market saleCommon Stock650$529$343.5K331,723
2026-07-27Open-market saleCommon Stock1,797$530$952.0K329,926
2026-07-27Open-market saleCommon Stock1,121$530$594.7K328,805
2026-07-27Open-market saleCommon Stock1,836$532$976.1K326,969
2026-07-27Open-market saleCommon Stock1,529$532$814.0K325,440
2026-07-27Open-market saleCommon Stock957$534$510.6K324,483
2026-07-27Open-market saleCommon Stock40$535$21.4K324,443
2026-07-27Option exercise/conversionStock Option9,500——265,410

Key Dates

DateDescription
2026-07-27Option exercise/conversion (9,500 shares)
2026-07-27Open-market sale (680 shares)
2026-07-27Open-market sale (890 shares)
2026-07-27Open-market sale (650 shares)
2026-07-27Open-market sale (1,797 shares)
2026-07-27Open-market sale (1,121 shares)
2026-07-27Open-market sale (1,836 shares)
2026-07-27Open-market sale (1,529 shares)
2026-07-27Open-market sale (957 shares)
2026-07-27Open-market sale (40 shares)
2026-07-27Option exercise/conversion (9,500 shares)

Keywords

insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.